Calcification in high grade XXXX treated with bevacizumab.

@entity1 @entity64 @entity548 @entity1313 @entity5 @entity11 @entity730 @entity463
UNASSIGNED: Calcification is a rare phenomenon in high grade @entity11 (HGG). CT scans are sensitive to mineralization but used infrequently for @entity5 assessment in the MRI era. The presence of @entity730 can be overlooked on routine MRI. Calcification may reflect chronicity and natural changes in the @entity5 or its milieu over time and may be accelerated by certain treatments. Calcification may have clinical significance which could signal potential risk for @entity64 or @entity548 related to particular therapies; or it may be a positive prognostic factor for treatment response. The true incidence and relevance of @entity730 in HGG and relation to therapy is unclear. During treatment of HGG @entity1 with bevacizumab (BVZ) we observed significant @entity5 @entity730 on brain CT. We performed a retrospective review of HGG @entity1 treated with BVZ to quantitate the incidence of @entity730 in this group compared to those treated with cytotoxic therapy alone. Sixty-two @entity1 with progressive HGG were treated with BVZ and a cytotoxic agent. Among 19 @entity1 treated for 6+ months, 12 had a CT scan performed. We observed an unexpected phenomenon of @entity730 in the CT scans of several @entity1 . We were also able to comparatively quantitate the incidence of @entity730 in a control group of @entity463 (GB) @entity1 not exposed to BVZ therapy. The incidence of @entity730 in the general GB population is increased with longer survival. The phenomenon is increased with anti-angiogenic therapy for @entity1313 . Calcification may have significance as a predictor for treatment response.
